viernes, 1 de mayo de 2020

Clinical Trials Update from NCI, April 2020

Clinical Trials Update from NCI, April 2020

National Cancer Institute banner



Clinical Trials
Updates from the National Cancer Institute
 
Clinical Trials News
 
Frederick National Laboratory for Cancer Research At NCI, A Robust and Rapid Response to the COVID-19 Pandemic


NCI Director Norman Sharpless, M.D., describes some of the COVID-19 specific research activities NCI has initiated and talks about the effect the coronavirus pandemic is having on cancer clinical trials.
 
Illustration of CAR T-cell therapy 

NCI is developing the capability to produce cellular therapies, like CAR T cells, to be tested in cancer clinical trials at multiple hospital sites. Few laboratories and centers have the ability to make CAR T cells, and that has limited the ability to test them more broadly.
 
NF1 patient and mother at NCI Selumetinib Approved by FDA to Treat Children with NF1


The Food and Drug Administration has approved selumetinib (Koselugo) to treat children with neurofibromatosis 1 (NF1), a genetic disorder that causes tumors to form throughout the nervous system. The approval was based on findings from a phase 2 clinical trial spearheaded by NCI’s Pediatric Oncology Branch.
Nurse administering a vaccine 

More than a decade after vaccination, women who had received a single dose of a human papillomavirus (HPV) vaccine continued to be protected against infection with HPV16 and 18, the two cancer-causing HPV types targeted by the vaccine. The new findings are from an extended follow-up of the NCI-sponsored Costa Rica HPV Vaccine Trial.
Woman with tablet computer 

Women with cervical or uterine cancer who received radiation to the pelvic region reported side effects much more often using an online reporting system called PRO-CTCAE than they did during conversations with their clinicians, a new study shows.
 
 
Clinical Trials Information for Patients and Caregivers
 
NCI-MATCH Trial (Molecular Analysis for Therapy Choice)


In the NCI-MATCH precision medicine trial, doctors examine tumor tissue from patients with advanced solid tumors, lymphomas, or myelomas that have stopped responding to treatment and assign patients to treatment based on the molecular profiles of their disease.
 
NCI-COG Pediatric MATCH


In this precision medicine clinical trial, children and adolescents with advanced cancers whose tumors have certain genetic mutations are being treated with drugs designed to target those mutations.
 
Clinical trials search Find NCI-Supported Clinical Trials


Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
 
 
NCI-Supported Clinical Trials That Are Recruiting Patients 
 
Immunotherapy Drug for Rare Central Nervous System Tumors


This phase 2 trial is testing the immunotherapy drug nivolumab (Opdivo) in people with rare tumors of the central nervous system that have not responded to or relapsed after standard treatment. Doctors want to see if stimulating the immune system with nivolumab will cause these tumors to shrink or stop them from growing.
 
Virtual Tobacco Treatment for Cancer Patients


This phase 2 trial studies how well smoking cessation treatment plans work for tobacco-dependent cancer patients when delivered virtually as part of their cancer care in community oncology practices. Researchers want to see if virtual information and counseling sessions can help people with cancer quit smoking.

No hay comentarios:

Publicar un comentario